文献速递慢阻肺

COPD 疗效试验与效果试验:研究设计如何影响结局与适用性

Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability.
PubMed 文献 · Eur Respir J · 2018-02-21

该研究比较了 Salford 肺研究(SLS,开放标签效果 RCT)与六项近期大规模疗效 RCT 的基线特征、医疗资源使用和结局,并计算 SLS 患者符合疗效试验纳入标准的比例。结果显示 SLS 患者年龄更大、女性及现吸烟者更多、合并症(含哮喘)更多、入组前急性加重史更常见,且中度/重度急性加重率、总体严重不良事件(SAE)及肺炎 SAE 发生率更高;最多 30% 的 SLS 患者符合 IIIa 期监管性急性加重研究纳入标准。提示疗效 RCT 患者代表性有限,解读结局及纳入指南时应考虑此点。

要点

  • 效果 RCT 患者比疗效 RCT 患者年龄更大、合并症更多、急性加重更频繁。
  • 最多 30% 效果 RCT 患者符合 IIIa 期监管性急性加重研究纳入标准。
  • 解读疗效 RCT 结果及制定 COPD 指南时应考虑人群代表性差异。

核心结论

  • 大型 COPD 疗效 RCT 患者与效果试验相比代表性有限,解读疗效 RCT 结局及纳入指南时应考虑此点。

研究设计与样本

  • 比较 Salford 肺研究(SLS,开放标签效果 RCT)与六项近期大规模疗效 RCT 的基线特征、医疗资源使用和结局。
  • 计算 SLS 患者中符合疗效 RCT 联合治疗纳入标准的比例。

主要发现

  • SLS 患者年龄更大、女性更多、现吸烟者更多、合并症(包括哮喘)更多、入组前急性加重更常见。
  • SLS 中中度或重度急性加重率、总体严重不良事件(SAE)发生率及肺炎 SAE 发生率更高。
  • 最多 30% 的 SLS 患者符合 IIIa 期监管性急性加重研究纳入标准。

临床怎么用

  • 临床解读 COPD 疗效 RCT 结果时,应意识到其纳入人群与常规实践患者存在差异。
  • 将疗效 RCT 证据应用于指南和临床决策时,需考虑效果试验所反映的更广泛患者特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Guidelines for chronic obstructive pulmonary disease (COPD) management are based largely on results from double-blind randomised controlled trials (RCTs) of efficacy. These trials have high internal validity and test whether a drug is efficacious, but they are conducted in highly selected populations that may differ significantly from patients with COPD seen in routine practice.We compared the baseline characteristics, healthcare use and outcomes between the Salford Lung Study (SLS), an open-label effectiveness RCT, with six recent large-scale efficacy RCTs. We also calculated the proportion of SLS patients who would have been eligible for inclusion in an efficacy RCT by applying the inclusion criteria used in efficacy trials of combination treatments.SLS patients were older, included more females and more current smokers, had more comorbidities (including asthma), and had more often experienced exacerbations prior to inclusion. In the SLS, rates of moderate or severe exacerbations, incidence of overall serious adverse events (SAEs), and SAEs of pneumonia were more frequent. A maximum of 30% of patients enrolled in the SLS would have been eligible for a phase IIIa regulatory exacerbation study.Patients in large COPD efficacy RCTs have limited representativeness compared with an effectiveness trial. This should be considered when interpreting efficacy RCT outcomes and their inclusion into guidelines.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Woodcock A, Boucot I, Leather DA, et al. Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. Eur Respir J. 2018. PMID: 29467200. doi:10.1183/13993003.01531-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。